Reza Hakkak
Concepts (256)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Soybean Proteins | 15 | 2024 | 161 | 3.720 |
Why?
| Obesity | 16 | 2024 | 1113 | 2.620 |
Why?
| Isoflavones | 7 | 2023 | 89 | 2.610 |
Why?
| Rats, Zucker | 16 | 2024 | 69 | 2.340 |
Why?
| Fatty Liver | 4 | 2023 | 127 | 2.120 |
Why?
| Caseins | 10 | 2023 | 80 | 1.920 |
Why?
| Rats | 37 | 2024 | 3300 | 1.730 |
Why?
| Liver | 15 | 2023 | 1109 | 1.650 |
Why?
| Colon | 4 | 2024 | 98 | 1.580 |
Why?
| 9,10-Dimethyl-1,2-benzanthracene | 6 | 2015 | 51 | 1.180 |
Why?
| Mammary Neoplasms, Experimental | 6 | 2010 | 122 | 1.130 |
Why?
| Animals | 42 | 2024 | 13150 | 1.060 |
Why?
| Diet | 10 | 2019 | 564 | 0.990 |
Why?
| Thinness | 3 | 2017 | 46 | 0.950 |
Why?
| Hepatitis | 1 | 2024 | 21 | 0.940 |
Why?
| Acute-Phase Proteins | 1 | 2024 | 24 | 0.940 |
Why?
| Lipopolysaccharides | 1 | 2024 | 191 | 0.860 |
Why?
| Membrane Glycoproteins | 1 | 2024 | 240 | 0.850 |
Why?
| Metformin | 1 | 2023 | 64 | 0.840 |
Why?
| Inflammation | 3 | 2024 | 604 | 0.830 |
Why?
| Carrier Proteins | 1 | 2024 | 304 | 0.830 |
Why?
| Carcinogens | 7 | 2015 | 199 | 0.750 |
Why?
| Anticarcinogenic Agents | 2 | 2017 | 34 | 0.740 |
Why?
| Body Weight | 10 | 2023 | 513 | 0.730 |
Why?
| Lactobacillaceae | 1 | 2020 | 1 | 0.710 |
Why?
| Bile Acids and Salts | 1 | 2020 | 75 | 0.680 |
Why?
| Ethanol | 10 | 2004 | 338 | 0.590 |
Why?
| Milk Proteins | 6 | 2002 | 78 | 0.570 |
Why?
| Butyrates | 1 | 2017 | 30 | 0.570 |
Why?
| Ovariectomy | 2 | 2014 | 119 | 0.550 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2024 | 388 | 0.500 |
Why?
| Dietary Supplements | 3 | 2019 | 441 | 0.500 |
Why?
| Oxidoreductases, N-Demethylating | 6 | 2000 | 32 | 0.500 |
Why?
| Plant Extracts | 1 | 2017 | 190 | 0.490 |
Why?
| Cytochrome P-450 Enzyme System | 7 | 2001 | 195 | 0.490 |
Why?
| Receptors, Leptin | 1 | 2014 | 44 | 0.480 |
Why?
| Osteoporosis | 2 | 2019 | 146 | 0.470 |
Why?
| Tibia | 1 | 2014 | 117 | 0.470 |
Why?
| Arginine | 1 | 2015 | 179 | 0.460 |
Why?
| Lumbar Vertebrae | 1 | 2014 | 98 | 0.450 |
Why?
| Rats, Sprague-Dawley | 22 | 2015 | 1595 | 0.430 |
Why?
| Cell Proliferation | 1 | 2017 | 1007 | 0.420 |
Why?
| Mammary Neoplasms, Animal | 2 | 2015 | 35 | 0.410 |
Why?
| Osteocytes | 1 | 2014 | 206 | 0.400 |
Why?
| Male | 26 | 2024 | 25093 | 0.400 |
Why?
| Benz(a)Anthracenes | 1 | 2010 | 3 | 0.370 |
Why?
| Colonic Neoplasms | 3 | 2001 | 162 | 0.370 |
Why?
| Dehydroepiandrosterone | 1 | 2010 | 15 | 0.370 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2010 | 89 | 0.340 |
Why?
| Soy Foods | 1 | 2009 | 20 | 0.340 |
Why?
| Interleukin-6 | 2 | 2023 | 264 | 0.310 |
Why?
| Female | 18 | 2023 | 26329 | 0.310 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 30 | 0.300 |
Why?
| Dietary Proteins | 5 | 2002 | 242 | 0.300 |
Why?
| Gene Expression | 2 | 2019 | 608 | 0.290 |
Why?
| Protons | 1 | 2007 | 69 | 0.290 |
Why?
| Bone Density | 3 | 2019 | 379 | 0.260 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2001 | 74 | 0.250 |
Why?
| Azoxymethane | 3 | 2001 | 11 | 0.240 |
Why?
| Diet, Reducing | 1 | 2024 | 36 | 0.230 |
Why?
| Metabolome | 1 | 2023 | 88 | 0.210 |
Why?
| C-Reactive Protein | 1 | 2023 | 142 | 0.200 |
Why?
| Endocrine System | 1 | 2001 | 16 | 0.190 |
Why?
| Chelating Agents | 1 | 2001 | 27 | 0.190 |
Why?
| Breast Neoplasms | 1 | 2009 | 1169 | 0.180 |
Why?
| Cytokine Receptor Common beta Subunit | 1 | 2019 | 2 | 0.180 |
Why?
| Methyltransferases | 1 | 2019 | 28 | 0.180 |
Why?
| RNA, Ribosomal, 16S | 1 | 2020 | 109 | 0.170 |
Why?
| Proteomics | 1 | 2021 | 328 | 0.160 |
Why?
| Alcohol Drinking | 2 | 1999 | 223 | 0.160 |
Why?
| Polymerase Chain Reaction | 1 | 2019 | 455 | 0.160 |
Why?
| Adipose Tissue | 1 | 2020 | 187 | 0.160 |
Why?
| Osteogenesis | 2 | 2019 | 351 | 0.150 |
Why?
| Diet, High-Fat | 1 | 2020 | 222 | 0.150 |
Why?
| HCT116 Cells | 1 | 2017 | 22 | 0.140 |
Why?
| Feces | 1 | 2017 | 132 | 0.140 |
Why?
| DNA Fragmentation | 1 | 2017 | 55 | 0.140 |
Why?
| Adiponectin | 1 | 2017 | 64 | 0.140 |
Why?
| Enteral Nutrition | 3 | 2000 | 146 | 0.140 |
Why?
| Alanine Transaminase | 2 | 2015 | 124 | 0.140 |
Why?
| Phylogeny | 1 | 2017 | 230 | 0.140 |
Why?
| Liver Neoplasms, Experimental | 1 | 1996 | 50 | 0.140 |
Why?
| Gastrointestinal Neoplasms | 1 | 1996 | 44 | 0.140 |
Why?
| Lipid Metabolism | 1 | 2017 | 175 | 0.130 |
Why?
| Leptin | 1 | 2017 | 140 | 0.130 |
Why?
| Protein Hydrolysates | 1 | 2015 | 6 | 0.130 |
Why?
| Aspartate Aminotransferases | 1 | 2015 | 45 | 0.130 |
Why?
| Cytochrome P-450 CYP2E1 | 6 | 2004 | 113 | 0.130 |
Why?
| Insulin | 1 | 2017 | 457 | 0.120 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 1806 | 0.120 |
Why?
| Isoenzymes | 2 | 2000 | 168 | 0.120 |
Why?
| Liver Diseases, Alcoholic | 2 | 2004 | 36 | 0.120 |
Why?
| Absorptiometry, Photon | 1 | 2014 | 154 | 0.120 |
Why?
| Cell Line | 1 | 2017 | 1002 | 0.120 |
Why?
| Dietary Carbohydrates | 3 | 2004 | 88 | 0.110 |
Why?
| Dietary Fats | 3 | 2004 | 133 | 0.110 |
Why?
| Intestine, Small | 1 | 1993 | 109 | 0.100 |
Why?
| Humans | 9 | 2019 | 49827 | 0.100 |
Why?
| Mammary Glands, Animal | 2 | 2002 | 69 | 0.100 |
Why?
| Time Factors | 4 | 2007 | 2912 | 0.100 |
Why?
| Apoptosis | 1 | 2017 | 1100 | 0.100 |
Why?
| Disease Models, Animal | 4 | 2019 | 1451 | 0.090 |
Why?
| Cytoprotection | 1 | 2010 | 35 | 0.090 |
Why?
| Central Nervous System Depressants | 3 | 2002 | 79 | 0.090 |
Why?
| Cytochrome P-450 CYP1A1 | 3 | 2001 | 26 | 0.090 |
Why?
| Drug Evaluation, Preclinical | 1 | 2010 | 144 | 0.090 |
Why?
| Organ Size | 3 | 2007 | 226 | 0.090 |
Why?
| Parenteral Nutrition, Total | 2 | 2002 | 31 | 0.090 |
Why?
| Mice | 2 | 2020 | 5720 | 0.090 |
Why?
| Signal Transduction | 1 | 2017 | 1617 | 0.090 |
Why?
| Weight Gain | 2 | 2001 | 240 | 0.080 |
Why?
| Tissue Extracts | 1 | 2007 | 13 | 0.080 |
Why?
| Least-Squares Analysis | 1 | 2007 | 43 | 0.080 |
Why?
| Estrogens | 1 | 2009 | 227 | 0.080 |
Why?
| Biotransformation | 1 | 2007 | 86 | 0.080 |
Why?
| Solubility | 1 | 2007 | 68 | 0.070 |
Why?
| Bone and Bones | 2 | 2019 | 468 | 0.070 |
Why?
| Aging | 2 | 2010 | 688 | 0.070 |
Why?
| RNA, Messenger | 5 | 2001 | 1105 | 0.070 |
Why?
| Adenocarcinoma | 2 | 2001 | 401 | 0.070 |
Why?
| Enzyme Induction | 4 | 2001 | 80 | 0.060 |
Why?
| Apoproteins | 2 | 1996 | 14 | 0.060 |
Why?
| Pregnancy | 4 | 2015 | 2584 | 0.060 |
Why?
| Cytochrome P-450 CYP1A2 | 2 | 2001 | 39 | 0.060 |
Why?
| Body Mass Index | 1 | 2007 | 652 | 0.060 |
Why?
| Cell Division | 2 | 2002 | 292 | 0.060 |
Why?
| Fatty Acids | 1 | 2004 | 143 | 0.060 |
Why?
| Asthma | 1 | 2007 | 283 | 0.060 |
Why?
| Cell Membrane | 1 | 2004 | 248 | 0.050 |
Why?
| Receptors, Glucocorticoid | 2 | 1993 | 32 | 0.050 |
Why?
| Energy Intake | 2 | 2019 | 170 | 0.050 |
Why?
| Overweight | 1 | 2005 | 219 | 0.050 |
Why?
| Receptors, Progesterone | 1 | 2002 | 63 | 0.050 |
Why?
| Infant Food | 1 | 2002 | 29 | 0.050 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2000 | 78 | 0.050 |
Why?
| Safrole | 1 | 2001 | 4 | 0.050 |
Why?
| Methylcholanthrene | 1 | 2001 | 10 | 0.050 |
Why?
| Food, Formulated | 1 | 2001 | 41 | 0.050 |
Why?
| Blotting, Western | 3 | 2001 | 602 | 0.050 |
Why?
| Risk Factors | 1 | 2009 | 3619 | 0.050 |
Why?
| Statistics, Nonparametric | 1 | 2001 | 197 | 0.050 |
Why?
| Testosterone | 1 | 2001 | 139 | 0.050 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2002 | 181 | 0.050 |
Why?
| Chemoprevention | 1 | 2000 | 14 | 0.040 |
Why?
| Cytochrome P-450 CYP2B1 | 1 | 1999 | 6 | 0.040 |
Why?
| Phytoestrogens | 1 | 2019 | 22 | 0.040 |
Why?
| Osteocalcin | 1 | 2019 | 43 | 0.040 |
Why?
| Cell Differentiation | 1 | 2002 | 653 | 0.040 |
Why?
| Estradiol | 1 | 2001 | 225 | 0.040 |
Why?
| Vagina | 1 | 2000 | 45 | 0.040 |
Why?
| Cattle | 1 | 2000 | 210 | 0.040 |
Why?
| Femur | 1 | 2019 | 133 | 0.040 |
Why?
| Hepatitis, Alcoholic | 1 | 1999 | 10 | 0.040 |
Why?
| Sex Factors | 1 | 2001 | 693 | 0.040 |
Why?
| Oxidoreductases | 2 | 2001 | 57 | 0.040 |
Why?
| Steroid Hydroxylases | 2 | 2000 | 18 | 0.040 |
Why?
| Analysis of Variance | 1 | 2000 | 565 | 0.040 |
Why?
| Amino Acids | 1 | 2019 | 358 | 0.040 |
Why?
| Cocarcinogenesis | 1 | 1996 | 14 | 0.040 |
Why?
| Duodenal Neoplasms | 1 | 1996 | 15 | 0.040 |
Why?
| Incidence | 1 | 2000 | 1003 | 0.030 |
Why?
| Digitoxin | 1 | 1975 | 3 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 1996 | 143 | 0.030 |
Why?
| Lymphocytes | 1 | 1996 | 151 | 0.030 |
Why?
| Nitrophenols | 1 | 1995 | 16 | 0.030 |
Why?
| Carbon Tetrachloride | 1 | 1995 | 22 | 0.030 |
Why?
| Protective Agents | 1 | 2015 | 14 | 0.030 |
Why?
| Growth | 1 | 1995 | 40 | 0.030 |
Why?
| Rats, Wistar | 1 | 1995 | 223 | 0.030 |
Why?
| Microsomes, Liver | 1 | 1975 | 186 | 0.030 |
Why?
| Dental Pulp Necrosis | 1 | 1974 | 1 | 0.030 |
Why?
| Periapical Granuloma | 1 | 1974 | 1 | 0.030 |
Why?
| Radicular Cyst | 1 | 1974 | 3 | 0.030 |
Why?
| Root Canal Therapy | 1 | 1974 | 3 | 0.030 |
Why?
| Pulsatile Flow | 1 | 1993 | 19 | 0.030 |
Why?
| Osmolar Concentration | 1 | 1993 | 62 | 0.030 |
Why?
| Homeostasis | 1 | 1993 | 199 | 0.030 |
Why?
| Leiomyosarcoma | 1 | 1992 | 23 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 1993 | 458 | 0.020 |
Why?
| Health Status Indicators | 1 | 2007 | 83 | 0.020 |
Why?
| Hand Injuries | 1 | 1976 | 21 | 0.020 |
Why?
| Cnidaria | 1 | 1976 | 2 | 0.020 |
Why?
| Sterols | 1 | 1976 | 8 | 0.020 |
Why?
| Exercise Therapy | 1 | 1976 | 98 | 0.020 |
Why?
| Dexamethasone | 2 | 1999 | 429 | 0.020 |
Why?
| Burns | 1 | 1976 | 163 | 0.020 |
Why?
| Glucocorticoids | 2 | 1999 | 219 | 0.010 |
Why?
| Corn Oil | 1 | 2004 | 12 | 0.010 |
Why?
| Free Radicals | 1 | 2004 | 28 | 0.010 |
Why?
| Malondialdehyde | 1 | 2004 | 51 | 0.010 |
Why?
| Antibodies | 1 | 2004 | 155 | 0.010 |
Why?
| Glutathione | 1 | 2004 | 295 | 0.010 |
Why?
| Animal Feed | 1 | 2002 | 57 | 0.010 |
Why?
| Intubation, Gastrointestinal | 1 | 2002 | 26 | 0.010 |
Why?
| Asia | 1 | 2002 | 20 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2007 | 1541 | 0.010 |
Why?
| Antioxidants | 1 | 2004 | 248 | 0.010 |
Why?
| Tumor Cells, Cultured | 2 | 1993 | 465 | 0.010 |
Why?
| Bone Development | 1 | 2002 | 65 | 0.010 |
Why?
| Fertilization | 1 | 2001 | 6 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 2002 | 376 | 0.010 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2001 | 25 | 0.010 |
Why?
| Blotting, Northern | 1 | 2001 | 109 | 0.010 |
Why?
| Cytosol | 1 | 2001 | 82 | 0.010 |
Why?
| Chlorzoxazone | 1 | 2000 | 5 | 0.010 |
Why?
| Cytokines | 1 | 2004 | 612 | 0.010 |
Why?
| Substrate Specificity | 1 | 2000 | 195 | 0.010 |
Why?
| Oxygenases | 1 | 1999 | 14 | 0.010 |
Why?
| Health Status | 1 | 2002 | 298 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2002 | 971 | 0.010 |
Why?
| Oxidative Stress | 1 | 2004 | 768 | 0.010 |
Why?
| Alcoholism | 1 | 2002 | 232 | 0.010 |
Why?
| Food-Drug Interactions | 1 | 1999 | 14 | 0.010 |
Why?
| Child, Preschool | 1 | 2007 | 3853 | 0.010 |
Why?
| Necrosis | 1 | 1999 | 177 | 0.010 |
Why?
| CD4-CD8 Ratio | 1 | 1996 | 9 | 0.010 |
Why?
| Lymphocyte Count | 1 | 1996 | 21 | 0.010 |
Why?
| Gene Expression Regulation | 1 | 2001 | 979 | 0.010 |
Why?
| Antigens, Surface | 1 | 1996 | 54 | 0.010 |
Why?
| Thymus Gland | 1 | 1996 | 42 | 0.010 |
Why?
| Digitoxigenin | 1 | 1975 | 4 | 0.010 |
Why?
| NADP | 1 | 1975 | 22 | 0.010 |
Why?
| Chromatography, Thin Layer | 1 | 1975 | 24 | 0.010 |
Why?
| Hydroxylation | 1 | 1975 | 61 | 0.010 |
Why?
| Spleen | 1 | 1996 | 173 | 0.010 |
Why?
| Infant, Newborn | 1 | 2002 | 2744 | 0.010 |
Why?
| Root Canal Filling Materials | 1 | 1974 | 2 | 0.010 |
Why?
| Formaldehyde | 1 | 1974 | 52 | 0.010 |
Why?
| Flow Cytometry | 1 | 1996 | 470 | 0.010 |
Why?
| Centrifugation, Density Gradient | 1 | 1993 | 17 | 0.010 |
Why?
| Precipitin Tests | 1 | 1993 | 33 | 0.010 |
Why?
| Antibody Specificity | 1 | 1993 | 36 | 0.010 |
Why?
| Triamcinolone Acetonide | 1 | 1993 | 15 | 0.010 |
Why?
| Immunoassay | 1 | 1993 | 20 | 0.010 |
Why?
| Subcellular Fractions | 1 | 1993 | 34 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 103 | 0.010 |
Why?
| Infant | 1 | 2002 | 3551 | 0.010 |
Why?
| Alcohol Dehydrogenase | 1 | 1993 | 38 | 0.010 |
Why?
| Radiography | 1 | 1974 | 489 | 0.010 |
Why?
| Receptors, Adrenergic, alpha | 1 | 1992 | 15 | 0.010 |
Why?
| Antigen-Antibody Complex | 1 | 1992 | 35 | 0.010 |
Why?
| Down-Regulation | 1 | 1993 | 349 | 0.010 |
Why?
| Cricetinae | 1 | 1992 | 192 | 0.010 |
Why?
| Neoplasms | 1 | 2002 | 1233 | 0.010 |
Why?
| United States | 1 | 2002 | 4838 | 0.010 |
Why?
| Neoplasm Proteins | 1 | 1992 | 323 | 0.010 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 1992 | 829 | 0.000 |
Why?
| Bandages | 1 | 1976 | 23 | 0.000 |
Why?
| Chromatography, Gas | 1 | 1976 | 14 | 0.000 |
Why?
| Methods | 1 | 1976 | 55 | 0.000 |
Why?
| Lipids | 1 | 1976 | 147 | 0.000 |
Why?
| Mass Spectrometry | 1 | 1976 | 306 | 0.000 |
Why?
| Adolescent | 1 | 1974 | 6340 | 0.000 |
Why?
| Aged | 1 | 1974 | 9272 | 0.000 |
Why?
| Middle Aged | 1 | 1974 | 11997 | 0.000 |
Why?
| Adult | 1 | 1974 | 13160 | 0.000 |
Why?
|
|
Hakkak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|